Role of T Cells in Mediating Glomerulonephritis

T 细胞在介导肾小球肾炎中的作用

基本信息

  • 批准号:
    6545628
  • 负责人:
  • 金额:
    $ 24.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-09-01 至 2006-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): In this application, we propose to investigate how antigen specific CD4+ T cells mediate glomerular injury, the first key step leading to glomerulonephritis (GN).T cell mechanisms have emerged as potentially the most important mediators in GN. However, antigen specific T cells are largely unanalyzed in existing GN models. It is unknown whether and how antigen specific T cells mediate glomerular injury in GN. Guided by our experience in T cell mediated autoimmune disease we are investigating the roles of T cells specific to autoantigen Col4alpha3NC1, a critical component of glomerular basement membrane, in a rat GN model. We discovered: 1) a 13-mer T cell peptide of Col4alpha3NC1 induced fatal GN similar to human late stage cresentic GN; 2) Col4alpha3NC1 specific CD4+ T cells of TH-1 type transferred severe GN in the naive recipients; 3) transfer of the T cells induced influx of monocytes/T cells into renal cortex. Thus, antigen specific CD4+ T cells may directly mediate glomerular injury and cause GN. Our hypothetical mechanism of glomerular injury mediated by antigen specific CD4+ T cells is as follows: 1. CD4+ T cells specific to autoantigen Col4alpha3NC1 are activated through molecular mimicry by microbial antigens; 2. activated T cells recognize a subpopulation of MHC class II+ glomerular cells; 3. recognition triggers monocytes/T cells influx into glomeruli; glomerular inflammation is initiated and maintained. With our unique model based on Col4alpha3 specific CD4 T cells and the T cell epitope, we will test our hypotheses: 1) We will identify a mimicking T cell peptide from microbial antigens based on the characterization of the 13-mer T cell peptide; 2) We will investigate the antigen presenting capacity of the MHC class II+ glomerular cell subpopulation, which may serve as the target for CD4+ T cells; 3) We will investigate the roles of infiltrating monocytes and T cells in the initiation and maintenance of glomerular inflammation after T cell transfer.
描述(由申请人提供):在本申请中,我们提出研究抗原特异性CD4 + T细胞如何介导肾小球损伤,这是导致肾小球肾炎(GN)的第一个关键步骤。然而,在现有的GN模型中,抗原特异性T细胞在很大程度上未被分析。目前尚不清楚抗原特异性T细胞是否以及如何介导肾小球损伤。根据我们在T细胞介导的自身免疫性疾病方面的经验,我们正在研究对自身抗原Col4 α 3NC 1(肾小球基底膜的关键成分)特异性的T细胞在大鼠GN模型中的作用。我们发现:1)Col4 α 3NC 1的13-mer T细胞肽诱导类似于人晚期新月体GN的致命性GN; 2)Col4 α 3NC 1特异性TH-1型CD 4 + T细胞在幼稚受体中转移严重GN; 3)T细胞的转移诱导单核细胞/T细胞流入肾皮质。因此,抗原特异性CD4 + T细胞可能直接介导肾小球损伤并引起GN。 我们假设抗原特异性CD4 + T细胞介导的肾小球损伤机制如下:1。对自身抗原Col4alpha3NC1特异性的CD4 + T细胞通过微生物抗原的分子模拟被激活; 2.活化的T细胞识别MHC II类+肾小球细胞的亚群; 3.识别触发单核细胞/T细胞流入肾小球;启动并维持肾小球炎症。我们将利用我们基于Col4 α 3特异性CD4 T细胞和T细胞表位的独特模型来验证我们的假设:1)我们将基于13-mer T细胞肽的特征鉴定来自微生物抗原的模拟T细胞肽:2)我们将研究MHC II类+肾小球细胞亚群的抗原呈递能力,其可能作为CD4 + T细胞的靶点; 3)研究T细胞移植后浸润的单核细胞和T细胞在肾小球炎症的发生和维持中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YAHUAN LOU其他文献

YAHUAN LOU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YAHUAN LOU', 18)}}的其他基金

A Novel Type of Dendritic Cell in Prevention of Glomerulonephritis
预防肾小球肾炎的新型树突状细胞
  • 批准号:
    8449742
  • 财政年份:
    2008
  • 资助金额:
    $ 24.94万
  • 项目类别:
A Novel Type of Dendritic Cell in Prevention of Glomerulonephritis
预防肾小球肾炎的新型树突状细胞
  • 批准号:
    7602997
  • 财政年份:
    2008
  • 资助金额:
    $ 24.94万
  • 项目类别:
A Novel Type of Dendritic Cell in Prevention of Glomerulonephritis
预防肾小球肾炎的新型树突状细胞
  • 批准号:
    8598160
  • 财政年份:
    2008
  • 资助金额:
    $ 24.94万
  • 项目类别:
A Novel Type of Dendritic Cell in Prevention of Glomerulonephritis
预防肾小球肾炎的新型树突状细胞
  • 批准号:
    8295656
  • 财政年份:
    2008
  • 资助金额:
    $ 24.94万
  • 项目类别:
A Novel Type of Dendritic Cell in Prevention of Glomerulonephritis
预防肾小球肾炎的新型树突状细胞
  • 批准号:
    8638947
  • 财政年份:
    2008
  • 资助金额:
    $ 24.94万
  • 项目类别:
CD8aa+ Cells and Ovarian Functions
CD8aa 细胞和卵巢功能
  • 批准号:
    7460882
  • 财政年份:
    2006
  • 资助金额:
    $ 24.94万
  • 项目类别:
CD8aa+ Cells and Ovarian Functions
CD8aa 细胞和卵巢功能
  • 批准号:
    7274679
  • 财政年份:
    2006
  • 资助金额:
    $ 24.94万
  • 项目类别:
CD8aa+ Cells and Ovarian Functions
CD8aa 细胞和卵巢功能
  • 批准号:
    7628134
  • 财政年份:
    2006
  • 资助金额:
    $ 24.94万
  • 项目类别:
CD8aa+ Cells and Ovarian Functions
CD8aa 细胞和卵巢功能
  • 批准号:
    7144388
  • 财政年份:
    2006
  • 资助金额:
    $ 24.94万
  • 项目类别:
CD8aa+ Cells and Ovarian Functions
CD8aa 细胞和卵巢功能
  • 批准号:
    7858175
  • 财政年份:
    2006
  • 资助金额:
    $ 24.94万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 24.94万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 24.94万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 24.94万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 24.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 24.94万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 24.94万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 24.94万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 24.94万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 24.94万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 24.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了